Transcranial Alternating Current Stimulation in Lewy Body Dementia
The aim of the study is to evaluate the safety, feasibility, clinical and biological efficacy, and predictors of efficacy of an intervention consisting of transcranial alternating current stimulation (tACS) in patients with Lewy Body Dementia (DLB). In neurodegenerative diseases, like DLB, the process of neurodegenerat
| Condition(s) | Lewy Body Dementia (LBD), Transcranial Alternating Current Stimulation |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | The aim of the study is to evaluate the safety, feasibility, clinical and biological efficacy, and predictors of efficacy of an intervention consisting of transcranial alternating current stimulation (tACS) in patients with Lewy Body Dementia (DLB). In neurodegenerative diseases, like DLB, the process of neurodegeneration is accompanied by a significant alteration in oscillatory activity. tACS is a neurophysiological method of non-invasive modulation of the excitability of the central nervous system that uses a mild electrical current. Recent studies have demonstrated the safety and efficacy of this method in modulating the natural brain oscillation frequencies underlying multiple cognitive processes, such as verbal memory, perception, and working memory. Preliminary data show that single |
| Who can participate | Inclusion Criteria: * Male or female subjects aged over 18 at the time of signing the informed consent form; * Presence of a clinical diagnosis of Lewy body dementia according to clinical criteria (McKeith et al., 2017) Exclusion Criteria: * Age younger than that stated in the inclusion criteria; * Incapacity to understand; * Contraindications for tACS and TMS: patients with cardiac pacemakers and metal implants that are not compatible with electric or magnetic fields, history of epilepsy, current pregnancy (Safety questionnaire) |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | IRCCS Centro San Giovanni di Dio Fatebenefratelli |
| Locations | Brescia, Italy, Italy |
| Start date | 2025-10-01 |
| NCT ID | NCT07375771 |
| Official listing | https://clinicaltrials.gov/study/NCT07375771 |